Increased Incidence of Glaucoma Medication Usage in Middle-aged Australian Males Taking Antiretroviral Medication - a Population-based Study

Overview

Journal J Ophthalmic Inflamm Infect

Publisher Springer

Specialty Ophthalmology

Date 2020 Nov 3

PMID 33141357

Citations 2

Authors

Wen-Shen Lee

Shaun Parsons

Dean Cugley

Sophie Rogers

Lyndell L Lim

Anthony Hall

Affiliations

Soon will be listed here.

Abstract

Background: To investigate a possible association between glaucoma and the use of anti-retroviral therapy (ART) for HIV in the Australian population.

Methods: A retrospective review of Australian Pharmaceutical Benefits Scheme data was undertaken from July 2012 to December 2016, inclusive. Three patient groups were compared: those on both topical intraocular pressure (IOP) -lowering medication and ART, those on ART only, and those on IOP-lowering medication only, using the 2016 Australian resident population to estimate prevalence. Odds ratios (95% confidence intervals, [CI]) with Fishers exact test for p values were calculated stratified by age and gender.

Results: The number of prescriptions for topical glaucoma medications in the general Australian population increased progressively by age with a peak prevalence in those aged 80 years and above. Prevalence of ART was highest in males aged 40-49 and 50-59 years (0.41% [CI 0.40, 0.42] and 0.44% [CI 0.43, 0.45], respectively). Our analysis identified an increase in the prescription of IOP-lowering medication in males on ART aged 30-39 (OR 2.23 [CI 1.32, 3.75], p = 0.007) and 40-49 (OR 1.86 [CI 1.42, 2.43], p < 0.001), compared to those not on ART. There were no statistically significant increased odds for females or males aged 50 years or more.

Conclusion: Compared with the known increase in glaucoma prevalence with age in the general Australian population, a statistically significant increased prevalence in use of IOP-lowering medications was found in males on ART aged 30-49 years. The mechanism for this is yet to be determined, but possible causes include sequelae of HIV infection, a drug-induced side effect, or increased medical surveillance.

Citing Articles

Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review.

Zhao Y, Tang Y, Wang Q, Li J Front Immunol. 2025; 16:1515768.

PMID: 39967658 PMC: 11832381. DOI: 10.3389/fimmu.2025.1515768.

Viral infections and pathogenesis of glaucoma: a comprehensive review.

Ahmad F, Deshmukh N, Webel A, Johnson S, Suleiman A, Mohan R Clin Microbiol Rev. 2023; 36(4):e0005723.

PMID: 37966199 PMC: 10870729. DOI: 10.1128/cmr.00057-23.

The Prevalence of Autoimmune Diseases in Patients with Primary Open-Angle Glaucoma Undergoing Ophthalmic Surgeries.

Lorenzo M, Devlin J, Saini C, Cho K, Paschalis E, Chen D Ophthalmol Glaucoma. 2021; 5(2):128-136.

PMID: 34416426 PMC: 8854449. DOI: 10.1016/j.ogla.2021.08.003.

References

Lucas S, Nelson A . HIV and the spectrum of human disease. J Pathol. 2014; 235(2):229-41. DOI: 10.1002/path.4449. View

Ances B, Letendre S . CROI 2019: neurologic complications of HIV disease. Top Antivir Med. 2019; 27(1):26-33. PMC: 6550359. View

Chan P, Hellmuth J, Spudich S, Valcour V . Cognitive Impairment and Persistent CNS Injury in Treated HIV. Curr HIV/AIDS Rep. 2016; 13(4):209-17. PMC: 4977199. DOI: 10.1007/s11904-016-0319-7. View

Klein B, Klein R, Sponsel W, Franke T, Cantor L, Martone J . Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 1992; 99(10):1499-504. DOI: 10.1016/s0161-6420(92)31774-9. View

Lang R, Read R, Krentz H, Ramazani S, Peng M, Gratrix J . Increasing incidence of syphilis among patients engaged in HIV care in Alberta, Canada: a retrospective clinic-based cohort study. BMC Infect Dis. 2018; 18(1):125. PMC: 5851255. DOI: 10.1186/s12879-018-3038-4. View

Jabs D, Drye L, Van Natta M, Thorne J, Holland G . Incidence and long-term outcomes of the human immunodefıciency virus neuroretinal disorder in patients with AIDS. Ophthalmology. 2015; 122(4):760-8. PMC: 4372475. DOI: 10.1016/j.ophtha.2014.11.009. View

Carelli V, Ross-Cisneros F, Sadun A . Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004; 23(1):53-89. DOI: 10.1016/j.preteyeres.2003.10.003. View

Jabs D, Van Natta M, Holbrook J, Kempen J, Meinert C, Davis M . Longitudinal study of the ocular complications of AIDS: 2. Ocular examination results at enrollment. Ophthalmology. 2007; 114(4):787-93. DOI: 10.1016/j.ophtha.2006.07.065. View

Jabs D, Van Natta M, Holbrook J, Kempen J, Meinert C, Davis M . Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment. Ophthalmology. 2007; 114(4):780-6. DOI: 10.1016/j.ophtha.2006.11.008. View

10.

Cunningham Jr E, Zierhut M . Uveitic Ocular Hypertension and Glaucoma. Ocul Immunol Inflamm. 2017; 25(6):737-739. DOI: 10.1080/09273948.2017.1415077. View

11.

Thean J, Hall A, Stawell R . Uveitis in Herpes zoster ophthalmicus. Clin Exp Ophthalmol. 2002; 29(6):406-10. DOI: 10.1046/j.1442-9071.2001.d01-29.x. View

12.

Erlandson K, Allshouse A, Jankowski C, Lee E, Rufner K, Palmer B . Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013; 208(2):249-59. PMC: 3685225. DOI: 10.1093/infdis/jit147. View

13.

Tenhula W, Xu S, Madigan M, Heller K, Freeman W, Sadun A . Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. Am J Ophthalmol. 1992; 113(1):14-20. DOI: 10.1016/s0002-9394(14)75746-0. View

14.

Malessa R, Agelink M, Diener H . Dysfunction of visual pathways in HIV-1 infection. J Neurol Sci. 1995; 130(1):82-7. DOI: 10.1016/0022-510x(95)00002-j. View

15.

Van Tassel S, Petrakos P, Marlow E, Mauer E, Singh H, Demetriades A . Retinal nerve fiber layer changes based on historic CD4 nadir among HIV positive patients undergoing glaucoma evaluation. Int J Ophthalmol. 2019; 12(5):789-794. PMC: 6520263. DOI: 10.18240/ijo.2019.05.14. View

16.

Demirkaya N, Wit F, Schlingemann R, Verbraak F . Neuroretinal Degeneration in HIV Patients Without Opportunistic Ocular Infections in the cART Era. AIDS Patient Care STDS. 2015; 29(10):519-32. DOI: 10.1089/apc.2015.0091. View

17.

Kim Y, Sun H, Kim T, Kang K, Lee S . Ocular Manifestations of Acquired Immunodeficiency Syndrome. Korean J Ophthalmol. 2015; 29(4):241-8. PMC: 4520867. DOI: 10.3341/kjo.2015.29.4.241. View

18.

Vajaranant T, Nayak S, Wilensky J, Joslin C . Gender and glaucoma: what we know and what we need to know. Curr Opin Ophthalmol. 2010; 21(2):91-9. PMC: 4326058. DOI: 10.1097/ICU.0b013e3283360b7e. View

19.

Margolis A, Heverling H, Pham P, Stolbach A . A review of the toxicity of HIV medications. J Med Toxicol. 2013; 10(1):26-39. PMC: 3951641. DOI: 10.1007/s13181-013-0325-8. View

20.

Grabar S, Tattevin P, Selinger-Leneman H, de La Blanchardiere A, De Truchis P, Rabaud C . Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015; 60(8):1269-77. DOI: 10.1093/cid/ciu1161. View